Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC By Ogkologos - July 14, 2025 819 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR FDA Approves Relugolix for Advanced Prostate Cancer January 7, 2021 EMA Recommends to Extend Therapeutic Indications for Crizotinib in Paediatric Patients July 26, 2024 NRG1 Fusion–positive Lung Cancers are Molecularly, Pathologically, and Clinically More Heterogeneous... June 8, 2021 An unexpected find: clues about the genetics of children’s cancer found... April 6, 2021 Load more HOT NEWS Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis,... Stopping Treatment Is a Reasonable Strategy for Patients with Advanced NSCLC... Screening Programme by Primary Colonoscopy or Two Rounds of Two-Stool FIT... Cancer Survivor with Strong Family History Was Denied Regular Screening Because...
